Mergers and Acquisitions in the Biotechnology Industry

2008 ◽  
pp. 133-148 ◽  
Author(s):  
Lars Schweizer ◽  
Dodo zu Knyphausen-Aufsess
Author(s):  
Tsai-Hsin Cheng ◽  
Chung-Jian Huang ◽  
Chao-Hsien Sung ◽  
Yi-Chang Huang

The worldwide lockdown caused by COVID-19 has led to the complete suspension of shipping, land transportation, and aviation. As a result of the redistribution of global resources, governments have recently advocated acquisitions and mergers with strategic alliances and vertical integrations to revitalize the economy. This study aims to investigate how the mergers and acquisitions (M&A) were negotiated and how the equilibrium price was achieved with game theory and information economics in agricultural and fishery biotechnology industry. The findings in the present study propose that by adopting investment valuation (asset-based approach, revenue method, market method) and presenting three patents (globally unique nondrug-denatured pure male tilapia and GPS [Formula: see text]C cloud cold chain logistics), the more the vulnerable company is able to attain a triumphant price during the negotiation of M&A.


Author(s):  
James F. Oehmke ◽  
Anwar Naseem

AbstractThis article explores the relationships among mergers and acquisitions (M&A), consolidation, concentration and inventive activity in the agricultural biotechnology industry. We adapt testable hypotheses from the conceptual literature. We empirically test each hypothesis and interpret the results in terms of existing explanations of consolidation and the level of inventive activity, and antitrust policy. We find aggregate inventive activity to be related to M&A activity, but whether the effect is positive or negative is dependent on the type of M&A. Further, greater number of public sector firms in the research market, as well as increasing industry concentration, are both found to increase overall innovation.


2011 ◽  
Author(s):  
Robin R. Cohen ◽  
Kim Stepanski ◽  
Miriam Ort ◽  
Eryn A. O'Brien

2002 ◽  
Vol 13 (2) ◽  
pp. 17
Author(s):  
A. Carr Conway ◽  
Robert W. Rouse

2009 ◽  
pp. 23-45 ◽  
Author(s):  
A. Radygin

The article deals with key tendencies in the development of Russia’s market of mergers and acquisitions in the first decade of the 21st century. Quantitative parameters are analyzed by using available in the open access data bases for the years 2003-2008 taking into consideration new tendencies relating to 2008 financial crisis. An active role of the state played in the market of corporate control represents an important factor. Special attention is given to issues of development of Russia’s system of legal norms regulating the market of mergers and acquisitions.


2007 ◽  
pp. 85-96 ◽  
Author(s):  
I. Kasparova

The article considers the financial tools of corporate control transfers and mergers and acquisitions financing forms. In western countries tax and informative factors are more important, but in the Russian business market lack of development of the stock market and low cost of securities of Russian companies play the main role. The analysis has shown that in Russia the monetary form of M&A financing dominates over other financing forms (90% of reviewed cases), still there are individual cases of M&A financing by buying company’s shares (10% of reviewed cases).


Author(s):  
Alexandra V. Chugunova ◽  
Olga A. Klochko

This research studies the relationship of cross-border mergers and acquisitions to international trade through the lens of Russian pharmaceutical market. To this aim, the study analyses the woks of foreign economists dedicated to evaluating the link between foreign direct investment and international trade, and the influence of mergers and acquisitions on countries’ export and import flows. The research also presents a correlation analysis between the volume of Russian pharmaceutical exports and imports and cross-border deals performed by foreign pharmaceutical companies in Russia. We characterize these deals and conduct a comparative analysis of the regional structure of Russian pharmaceutical exports and imports as well as of the countries of origin of buyers in cross-border mergers and acquisitions. The results of the analysis indicate a positive relationship between cross-border mergers and acquisitions and Russian pharmaceutical exports, which is reflected in the export volume growth and its geographical diversification. However, it is outlined that particular problems of the industry hinder the amelioration of Russian positions in international exports. Similarly, the relationship between cross-border deals and Russian imports is positive: the major pharmaceutical products supply flow occurs from the countries of origin of buyers in cross-border mergers and acquisitions conducted in the Russian pharmaceutical sector.


Sign in / Sign up

Export Citation Format

Share Document